Logo image of 1MRNA.MI

MODERNA INC (1MRNA.MI) Stock Fundamental Analysis

BIT:1MRNA - Euronext Milan - US60770K1079 - Common Stock - Currency: EUR

22.745  -0.32 (-1.39%)

Fundamental Rating

4

Taking everything into account, 1MRNA scores 4 out of 10 in our fundamental rating. 1MRNA was compared to 71 industry peers in the Biotechnology industry. The financial health of 1MRNA is average, but there are quite some concerns on its profitability. 1MRNA is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

2

1. Profitability

1.1 Basic Checks

In the past year 1MRNA has reported negative net income.
In the past year 1MRNA has reported a negative cash flow from operations.
The reported net income has been mixed in the past 5 years: 1MRNA reported negative net income in multiple years.
In multiple years 1MRNA reported negative operating cash flow during the last 5 years.
1MRNA.MI Yearly Net Income VS EBIT VS OCF VS FCF1MRNA.MI Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 5B 10B

1.2 Ratios

1MRNA has a Return On Assets (-26.42%) which is in line with its industry peers.
1MRNA's Return On Equity of -33.35% is fine compared to the rest of the industry. 1MRNA outperforms 60.56% of its industry peers.
Industry RankSector Rank
ROA -26.42%
ROE -33.35%
ROIC N/A
ROA(3y)-6.14%
ROA(5y)4.17%
ROE(3y)-7.66%
ROE(5y)6.83%
ROIC(3y)N/A
ROIC(5y)N/A
1MRNA.MI Yearly ROA, ROE, ROIC1MRNA.MI Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20 -20 40 -40 60 80

1.3 Margins

1MRNA's Gross Margin of 68.68% is fine compared to the rest of the industry. 1MRNA outperforms 67.61% of its industry peers.
1MRNA's Gross Margin has declined in the last couple of years.
1MRNA does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 68.68%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-6.55%
GM growth 5YN/A
1MRNA.MI Yearly Profit, Operating, Gross Margins1MRNA.MI Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -200 -400 -600 -800

More info and screens

6

2. Health

2.1 Basic Checks

1MRNA does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for 1MRNA has been increased compared to 1 year ago.
Compared to 5 years ago, 1MRNA has more shares outstanding
The debt/assets ratio for 1MRNA has been reduced compared to a year ago.
1MRNA.MI Yearly Shares Outstanding1MRNA.MI Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M
1MRNA.MI Yearly Total Debt VS Total Assets1MRNA.MI Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 5B 10B 15B 20B 25B

2.2 Solvency

An Altman-Z score of 3.15 indicates that 1MRNA is not in any danger for bankruptcy at the moment.
Looking at the Altman-Z score, with a value of 3.15, 1MRNA belongs to the top of the industry, outperforming 81.69% of the companies in the same industry.
A Debt/Equity ratio of 0.00 indicates that 1MRNA is not too dependend on debt financing.
1MRNA has a Debt to Equity ratio of 0.00. This is amongst the best in the industry. 1MRNA outperforms 90.14% of its industry peers.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 3.15
ROIC/WACCN/A
WACC10.01%
1MRNA.MI Yearly LT Debt VS Equity VS FCF1MRNA.MI Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 5B 10B 15B

2.3 Liquidity

1MRNA has a Current Ratio of 4.22. This indicates that 1MRNA is financially healthy and has no problem in meeting its short term obligations.
1MRNA's Current ratio of 4.22 is fine compared to the rest of the industry. 1MRNA outperforms 77.46% of its industry peers.
A Quick Ratio of 4.14 indicates that 1MRNA has no problem at all paying its short term obligations.
With a decent Quick ratio value of 4.14, 1MRNA is doing good in the industry, outperforming 78.87% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 4.22
Quick Ratio 4.14
1MRNA.MI Yearly Current Assets VS Current Liabilites1MRNA.MI Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 5B 10B 15B

More info and screens

6

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 44.29% over the past year.
The Revenue for 1MRNA has decreased by -38.35% in the past year. This is quite bad
Measured over the past years, 1MRNA shows a very strong growth in Revenue. The Revenue has been growing by 122.01% on average per year.
EPS 1Y (TTM)44.29%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%17.92%
Revenue 1Y (TTM)-38.35%
Revenue growth 3Y-44.04%
Revenue growth 5Y122.01%
Sales Q2Q%-35.33%

3.2 Future

The Earnings Per Share is expected to grow by 18.49% on average over the next years. This is quite good.
Based on estimates for the next years, 1MRNA will show a very strong growth in Revenue. The Revenue will grow by 20.30% on average per year.
EPS Next Y-12.35%
EPS Next 2Y6.46%
EPS Next 3Y13.02%
EPS Next 5Y18.49%
Revenue Next Year-34.88%
Revenue Next 2Y-15.76%
Revenue Next 3Y-4.3%
Revenue Next 5Y20.3%

3.3 Evolution

Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
1MRNA.MI Yearly Revenue VS Estimates1MRNA.MI Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 5B 10B 15B
1MRNA.MI Yearly EPS VS Estimates1MRNA.MI Yearly EPS VS EstimatesYearly EPS VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 10 -10 20

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for 1MRNA. In the last year negative earnings were reported.
Also next year 1MRNA is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
1MRNA.MI Price Earnings VS Forward Price Earnings1MRNA.MI Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
1MRNA.MI Per share data1MRNA.MI EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 10 20

4.3 Compensation for Growth

A more expensive valuation may be justified as 1MRNA's earnings are expected to grow with 13.02% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y6.46%
EPS Next 3Y13.02%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for 1MRNA!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

MODERNA INC

BIT:1MRNA (5/23/2025, 7:00:00 PM)

22.745

-0.32 (-1.39%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-01 2025-05-01/bmo
Earnings (Next)07-30 2025-07-30/bmo
Inst Owners73.88%
Inst Owner ChangeN/A
Ins Owners5.45%
Ins Owner ChangeN/A
Market Cap8.79B
Analysts64.24
Price Target41.15 (80.92%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)7.48%
Min EPS beat(2)-6.26%
Max EPS beat(2)21.22%
EPS beat(4)3
Avg EPS beat(4)30%
Min EPS beat(4)-6.26%
Max EPS beat(4)101.54%
EPS beat(8)6
Avg EPS beat(8)-10.14%
EPS beat(12)8
Avg EPS beat(12)-0.55%
EPS beat(16)11
Avg EPS beat(16)3.53%
Revenue beat(2)1
Avg Revenue beat(2)0.08%
Min Revenue beat(2)-0.3%
Max Revenue beat(2)0.45%
Revenue beat(4)3
Avg Revenue beat(4)31.23%
Min Revenue beat(4)-0.3%
Max Revenue beat(4)78.74%
Revenue beat(8)7
Avg Revenue beat(8)29.59%
Revenue beat(12)9
Avg Revenue beat(12)24.91%
Revenue beat(16)12
Avg Revenue beat(16)19.49%
PT rev (1m)-15.03%
PT rev (3m)-39.65%
EPS NQ rev (1m)4.82%
EPS NQ rev (3m)-0.85%
EPS NY rev (1m)-0.61%
EPS NY rev (3m)-5.17%
Revenue NQ rev (1m)5.35%
Revenue NQ rev (3m)-30.57%
Revenue NY rev (1m)-3.61%
Revenue NY rev (3m)-13.05%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 3.13
P/FCF N/A
P/OCF N/A
P/B 0.99
P/tB 1
EV/EBITDA N/A
EPS(TTM)-7.72
EYN/A
EPS(NY)-7.12
Fwd EYN/A
FCF(TTM)-9.23
FCFYN/A
OCF(TTM)-6.99
OCFYN/A
SpS7.27
BVpS23.04
TBVpS22.81
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -26.42%
ROE -33.35%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 68.68%
FCFM N/A
ROA(3y)-6.14%
ROA(5y)4.17%
ROE(3y)-7.66%
ROE(5y)6.83%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-6.55%
GM growth 5YN/A
F-Score5
Asset Turnover0.25
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 511.46%
Cap/Sales 30.91%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 4.22
Quick Ratio 4.14
Altman-Z 3.15
F-Score5
WACC10.01%
ROIC/WACCN/A
Cap/Depr(3y)261.63%
Cap/Depr(5y)224.68%
Cap/Sales(3y)14.96%
Cap/Sales(5y)10.95%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)44.29%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%17.92%
EPS Next Y-12.35%
EPS Next 2Y6.46%
EPS Next 3Y13.02%
EPS Next 5Y18.49%
Revenue 1Y (TTM)-38.35%
Revenue growth 3Y-44.04%
Revenue growth 5Y122.01%
Sales Q2Q%-35.33%
Revenue Next Year-34.88%
Revenue Next 2Y-15.76%
Revenue Next 3Y-4.3%
Revenue Next 5Y20.3%
EBIT growth 1Y32.09%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-1.39%
EBIT Next 3Y15.37%
EBIT Next 5Y18.31%
FCF growth 1Y-759.15%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-407.35%
OCF growth 3YN/A
OCF growth 5YN/A